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Abstract
Background: Health Related Quality of Life has been used in medical research for more than twenty years, being
progressively accepted during the last decade as an important patient reported outcome. Considering the
multidimensional approach involved in Health Related Quality of Life assessment, instrument applicability and
cultural adaptation must be tested for each population. In order to select the most appropriate instrument for
Head and Neck cancer patients, two major Health Related Quality of Life specific questionnaires for Head and Neck
cancer patients were compared. Conceptual differences, psychometric characteristics, scores, reliability, construct
validity and sensitivity to symptomatology, tumour location, tumour size were analyzed.
Methods: 102 consecutive Head and Neck cancer patients completed two different Health Related Quality of Life
questionnaires: EORTC QLQ-C30 and its specific head and neck module QLQ-H&N35 and the Functional
Assessment of Cancer Therapy Scales (FACT-H&N). Patients completed the questionnaires, immediately before
consultation as a part of the routine evaluation.
Results: A greater variability was always found in the EORTC QLC-C30 questionnaire’s scores for all comparable
domains. Both instruments revealed a good internal consistency and demonstrated to be good tools to distinguish
symptomatic patients. The EORTC questionnaires still demonstrated sensitivity to distinguish T3 and T4 staging.
Conceptual differences and the psychometric characteristics are discussed. Our results suggest that these two
instruments assess different aspects of Health Related Quality of Life - the questionnaires should be used separately
and chosen according to the study objectives and methodology.
Conclusions: This study emphases the importance in selecting the appropriate tool as a critical success factor in
implementing routine Health Related Quality of Life assessment in clinical practice. This decision assumes
particularly importance when utilization of results in real time and integration into clinical protocols are considered.
Background
Health related Quality of Life Quality of life (HRQoL) is
by definition a multi-dimensional global construct,
introduced as keyword in the United States National
Library of Medicine in 1977 [1,2]. HRQoL, has been
used in medical research for more than twenty years,
and has been introduced in clinical practice as an
important outcome parameter in present medicine prac-
tice according to the contemporary holistic approach to
the patient [3,4].
Over the past 10 years, HRQoL has been progressively
more accepted as an important patient outcome result
in oncology along with the other conventional outcomes
used before such as treatment success, mean survival,
disease free survival or cancer controlled survival [5,6].
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in head and neck cancer patients
Head and neck cancer is undoubtedly related to a
decrease in HRQoL. After diagnosis, the treatment most
frequently determines a deterioration of basic functions
such as breathing, mastication, salivating, swallowing
and speaking. Sense’s impairment such as hearing, taste
and smell along with possible esthetics changes will pro-
mote a negative impact in both patients and their rela-
tives HRQoL [1,4,7].
HRQoL assessment allows head and neck cancer
patients careful monitoring, may recognize risk patient
groups being predictive for time to progression suggest-
ing this evaluation as a new prognostic marker for survi-
val [8-10]. HRQoL questionnaires enable patient’s
clustering according to their most frequent health con-
cerns, ranking its intensity [1,11]. Also, HRQoL assess-
ment can be considered a stimulating approach for
effectiveness and the cost-effectiveness promotion (survi-
val and quality-adjusted survival) contributing thus to the
construction of an economical decision model [12-14].
Instruments for HRQoL assessment in head and neck
cancer patients
HRQoL instruments must exhibit comproved psycho-
metric characteristics, such as: consistency, reliability,
reproducibility, validity and sensibility to change.
Considering the multidimensional approach involved
in the HRQoL assessment, instrument applicability and
cultural adaptation must be tested for each population.
The instruments that fulfill the minimal requisites for
Oncology HRQoL assessment include: Breast Cancer Che-
motherapy Questionnaire (BCQ), Cancer Rehabilitation
Evaluation Systems (CARES), European Organization for
Research and Treatment of Cancer Quality of Life Ques-
tionnaire (EORTC-QLQ), Functional Assessment of Can-
cer Therapy Scales (FACT), Functional Living Index Scale
(FLIC), Linear Analogue Self-Assessment, Medical Out-
come Study Short Form (MOS SF-36), Multidimensional
Quality of Life Scale, Quality of Life Index (QL- Index)
(Spitzer Index), Rotterdam Symptom Check List (RSCL)
[5,15,16]. The questionnaires EORTC-QLQ C30, FACT-
G, MOS SF-36 and FLIC stand out as the main general in
oncology.
There are specific instruments for head and neck cancer
patients HRQoL evaluation such as: the EORTC QLQ-
H&N35, the FACT H&N, the FLIC, the University of
Washington Quality of Life Questionnaire (UW-QOL),
the University of Michigan Head and Neck Quality of Life
Questionnaire (HNQOL), the Head and Neck Radiother-
apy Questionnaire (HNRQ), the Performance Status Scale-
Head and Neck-(PSS-H&N), the Obturator Functioning
Scale (OFS), the Late Side Effects on Daily Life Scale and
the Oral and Pharyngeal Nursing Care Questionnaire
(OPNCQ) [17-23].
Clinical trials and clinical practice
HRQoL has been used as a health outcome measure
mainly associated to clinical trials. The implementation of
routine HRQoL assessment in clinical practice can be
used for scientific documentation as well for clinical set-
tings [24-26]. This advance is fundamental to obtain clini-
cal meaningful data that can be a helpful outcome
considering patients undergoing cancer treatments and,
particularly, when additional supportive services and
symptom management are concerned. Moreover, the care-
ful HRQoL monitoring of cancer patients may identify
potentially unmet needs and generate the basis of a
stepped care model [26-28]. HRQoL information can thus
support clinical decisions and promote health gains. How-
ever, results obtained either from clinical practice or
research must be interpreted, not only in statistical terms,
but also considering the clinical importance - it is required
then an wide comprehension of the relationship between
the patients outcome results and the patients perception
of the change [29,30].
T h ep r e s e n ts t u d ya i m st oc o m p a r et h et w om a j o r
HRQoL questionnaires specific for head and neck cancer
patients: the EORTC QLQ-C30 and its specific head and
neck module QLQ-H&N35 and the Functional Assess-
ment of Cancer Therapy Scales (FACT H&N) in the Por-
tuguese Institute for Oncology, Porto (IPO-Porto).
Conceptual differences, psychometric characteristics and
scores are analyzed and discussed. A major attention is
made on significant differences that can be related to
clinical important data.
Methods
Patients
From September 2008 to January 2010, 102 outpatients
admitted to the Otorhinolaringology service (ORL ser-
vice) IPO-Porto, Portugal, completed two different
HRQoL questionnaires, immediately before consultation
as a part of the routine evaluation. The completion
order was randomized. Inclusion criteria were a Kar-
nofsky index above 30, age below 90 years, ability to
understand written and spoken Portuguese and provi-
sion of written consent.
Questionnaires
The questionnaires under comparison were from the
European Organisation for Research and Treatment of
Cancer (EORTC) and the Functional Assessment of
Cancer Therapy (FACT), both targeted to cancer
patients. HRQoL was assessed by general questionnaires,
EORTC QLQ-C30 and Functional Assessment of
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specific modules for head and neck (FACT H&N) can-
cer patients was also considered, the QLQ-H&N35 and
the FACT H&N, respectively. Scores and conceptual
characteristics were compared: between the two core
questionnaires - EORTC-QLQC30/FACT-G - and
between their disease-specific modules/extensions for
H&N patients - QLQ-H&N35/FACT H&N (FACT-G +
12 H&N-specific questions), respectively.
EORTC QLQ-C30 and the disease-specific module
QLQ-H&N35
The EORTC QLQ-C30 (version 3.0) is a questionnaire
developed to assess the HRQoL of cancer patients. It
consists of 30 questions: twenty four form nine multi-
item scales presenting various aspects of HRQoL: five
functional scales (PF, Physical functioning; SF, Social
functioning; EF, Emotional functioning; RF, Role func-
tioning; CF, Cognitive functioning), three symptom scales
(fatigue, pain, nausea and vomiting) and a global condi-
tion (health and quality of life). The remaining six are
single-item scales describing different cancer relevant
symptoms. During the scoring procedure, raw EORTC
QLQ-C30 scores are linearly transformed into 0 e100
scales. For global health status and the five functioning
scales, a score of 100 corresponds to a high HRQoL. For
financial difficulties and the eight symptoms, a score of
100 implies maximum difficulty or symptom burden. The
additional module - QLQ-H&N35 (version 3.0) - is dis-
ease-specific for head and neck patients. It consists of
35 questions organized in seven symptoms multi-item
scales (twenty four questions are presented) and eleven
are single-item scales describing different specific con-
cerns of these head and neck cancer patients.
FACT-G and the disease-specific FACT H&N
T h eF A C TH & N( v e r s i o n4 )i sam ultidimensional, self-
report HRQoL instrument specifically designed for use
with head and neck cancer patients. It consists of 27 core
items - FACT-G - assessing patient function in four
domains: Physical, Social/Family, Emotional, and Func-
tional well-being (Pwb, Swb, Ewb, and Fwb, respectively).
It is further supplemented by 12 site specific items for
head and neck related symptoms assessment - FACT -
(H&N-G). Each item is rated on a 0 to 4 Likert type scale,
and then combined to produce subscale scores for each
domain, as well as a global HRQoL score. Higher scores
represent better QoL.
Questionnaire completion
The autonomy expressed for questionnaire completion
as well the time patient needed to complete both ques-
tionnaires - EORTC QLQ-C30 (version 3)/QLQ H&N35
and FACT H&N - was evaluated.
Sociodemographic and clinical data
Clinical data - such as tumour location, performance
status (Karnofsky index), tobacco habits and present
symptomatology - as well socio-demographic data - age,
gender and schooling years - were collected from the
patient’s clinical process and complemented, when
needed, in semi structured interviews.
Ethics
All patients gave their informed consent. The data were
collected for research purposes as part of the routine
evaluation. The Committee for Ethics in Medical
Research approved the use of these data for research.
Analysis Strategies and Statistics
Completed questionnaires were scored according to the
developers’ instructions.
For tool comparison, 4 similar domains were always
considered in EORTC QLQ-C30 and FACT-G, respec-
tively: PF/Pwb, EF/Ewb, SF/Swb and RF/Fwb.
Descriptive data are presented with means, SDs, med-
ians, ranges, and proportions as appropriate.
Instrument’s scores characteristics
In probability theory and statistics, skewness is a measure
of the asymmetry of the probability distribution of a real-
valued random variable. Qualitatively, a negative skew
indicates that the tail on the left side of probability den-
sity function is longer than the right side and the bulk of
the values (including the median) lie to the right of the
mean. A positive skew indicates that the tail on the right
side is longer than the left side and the bulk of the values
lie to the left of the mean. Kurtosis is a measure of the
“peakedness” of the probability distribution of a real-
valued random variable. Higher kurtosis means more of
the variance is the result of infrequent extreme devia-
tions, as opposed to frequent modestly sized deviations.
Reliability
Reliability expressed as internal consistency is a measure
of how well the items in a multi-item scale interrelate.
This is usually assessed by computing Cronbach’s coeffi-
cient (Cronbach’s alpha). The score reflects both the
number of items and the degree of correlation between
items.
Sensitivity
Sensitivity measures how well the instrument identifies
differences between groups. An instrument with a high
sensitivity is able to detect a relatively small difference
with a modest sample size. Sensitivity is measured by
comparing the scores of different groups of patients. In
this study the patient population was divided: i) in two
groups according to the expressed symptomatology
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groups according tumour location (vocal cord neofor-
mation, laryngeal neoformation, pharynx neoformation,
pharynxlaryngeal neoformation, and tongue neoplasia),
iii) into four broad groups according tumour size (T1,
T2 T3 and T4) and iv) into four broad groups according
age (less than 45 year old, 46-55 years old, 56-65 years
old and older than 65). The scores were compared using
the Mann-Whitney or Kruskal-Wallis tests. Based on
clinical experience, significant differences between these
patient groups were expected.
Construct Validity
Construct validation evaluates how well an instrument
measures the construct it is intended to measure. Con-
vergence between instruments (external convergent
validity) is an assessment of the correlation between
EORTC and FACT measures of the same concept. This
is included in the multi-trait multi-method (MTMM)
analysis where Pearson’s correlations are used to com-
pute the degree of correlation. A correlation above 0.70
between scales measuring the same concept is consid-
ered to be an indication of the same underlying concept.
Discriminant validity was analysed to verify if the
HRQoL operationalization does not correlate with other
operationalizations that theoretically should not be cor-
related with.
Results
Patients Characteristics
One hundred two patients with median age of 59.4 years
(range, 22-90 years) participated in this study by com-
pleting the questionnaires. The patient characteristics
are summarized in Table 1.
Patients presented 59.4 ± 12.1 years and revealed a
low educational level presenting 5 ± 3 schooling years
and long tobacco habits being the majority (60.6%)
exposed for more than 31 years.
The Karnofsky performance status scale revealed that
all patients performed above 50% and 57% of head and
neck cancer patients were mainly ascribed to high Kar-
nofsky Index (90-100%).
Questionnaire completion
The time response varied between 3 and 20 minutes (9,3
± 3,1) for EORTC QLQ-C30 (version 3)/QLQ H&N35
and 3 to 23 minutes (7,3 ± 2,7) for FACT-H&N. Most
head and neck cancer patients (79,4%) required some
kind of help to answer the questionnaires.
Questionnaire’s conceptual characteristics
Main features of the two instruments used in this study
are depicted in Table 2. It is observed EORTC question-
naires are always longer, both core (30 compared to 27
in FACT-G) and disease specific modules (35 and 12 in
FACT- (H&N-G)). EORTC is always composed of scales
and simple item questions but the disease-specific mod-
ule in FACT is composed of simple items.
Instrument’s scores characteristics
A greater variability was always found in the EORTC
QLC-C30 questionnaire’s scores for all comparable
domains - PF and Pwb, EF and Ewb, SF and Swb and
finnally RF and Fwb. Asymmetry and flatness measures
found in PF and Pwb evidenced great similarity within
tools with the distribution tending to the left (-0.78 and
Table 1 Sociodemographic and clinical characteristics of
the participants (n = 102)
Categories n (%)
Gender Male 88 (86.3)
Female 14 (13.7)
Schooling (years) None 4 (3.9)
1-4 70 (68.6)
5-9 11 (10.8)
10+ 17 (16.7)
Tumour location Vocal cord 18 (18.8)
Laryngeal 17 (17.7)
Pharynx 13 (13.5)
Pharynx Laryngeal 6 (6.3)
Tongue 5 (5.2)
Others 37 (38.5)
Tumour diagnosis Spinocellular carcinoma 77 (75.4)
Displasic premalignant lesions 3 (3)
Other diagnosis 15 (14.7)
No diagnosis 7 (6.9)
Symptomatology Symptomatic 53 (52.0)
Asymptomatic 32 (31.4)
Missing 17 (16.7)
Table 2 Relevant instrument’s characteristics
EORTC-QLQ
C30
FACT-G EORTC
H&N35
FACT-
(H&N-
G)
No. of items 30 27 35 12
Global score No Yes No Yes
Scales 5 functional 4
functional
7 symptom None
3 symptom
2 global
Simple
items
6 0 11 12
EORTC QLQ-C30, European Organisation for Research and Treatment of
Cancer Quality of Life - Core 30.
EORTC H&N35, European Organisation for Research and Treatment of Cancer,
Head and Neck.
FACT-G, Functional Assessment of Cancer Therapy - General.
FACT H&N, Functional Assessment of Cancer Therapy, Head and Neck.
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platokurtic distribution (-0.22 versus -0.27) as illustrated
in Table 3.
Concerning SF and Swb, the most evident difference
was the extent of the flattening where FACT-G showed
a leptokurtic distribution (-0.67) and EORTC QLQ- C30
a platikurtic one (-0.84). The EF and Ewb domain pre-
sented similar measurement’s distribution and may be
considered as normal; RF and Fwb revealed a similar
distribution in shape. The Cognitive domain exhibited a
distribution very skewed to the right (-1.78).
When the disease-specific module EORTC QLQ-
H&N35 scales are considered, it was found a wide score
distribution as illustrated in Table 4. Less sexuality and
Senses Problems scores were found to be right skewed
(1.60 and 1.42, respectively).
Reliability
When internal consistency was compared by measuring
how well the items interrelate, EORTC demonstrated a
higher total consistency, both in the core questionnaire
EORTC QLQ-C30 (a = 0.87 versus 0.76 for FACT-G) as
well in the disease specific module H&N35 (a = 0.90 ver-
sus 0.79 for FACT - (H&N-G)). Most values observed
(Table 3, 4) were above 0.7 although the EF scale was
found below in both questionnaires, EORTC QLQ-C30
and FACT-G (a = 0.46 and 0.69, respectively). Cognitive
functioning scale revealed a low reliability (0.27).
The disease-specific module H&N35 revealed an inter-
nal consistency in all scales (a = 0.72 to 0.99) except in
Speech problems (a = 0.46).
Patient symptoms Sensitivity
Both core instruments detected significant differences
between symptomatic and asymptomatic patients.
EORTC QLQ-C30 detected differences in all scores
except the EF scale and the single items Insomnia and
Diarrhea. The symptomatic scores were always lower
being Fatigue and RF the exceptions. FACT-G revealed
to be sensitive in all domains except the Swb (Table 5).
D i s e a s es p e c i f i cm o d u l eE O R T CQ L Q - H & N 3 5w a s
also able to discriminate in all scales except Senses pro-
blems nor three simple item questions considering Dry
mouth, Weight loss and Weight loss. FACT - (H&N-G)
was found to be sensitive when total score was consid-
ered and statistical significant differences were found in
5 single items (questions 1, 5, 7, 10 and 11).
Tumour location sensitivity
EORTC QLQ-C30 revealed no sensitivity to tumour
location being Fatigue in the discrimination boundary
for Vocal cord neoformation (p = 0.05). The Pwb in
FACT-G is sensitive to Vocal cord neoformation loca-
tion (p = 0.008) presenting higer HRQoL score.
Vocal cord neoformation location was also positively
discriminated when Swallowing, Trouble with social
Table 3 EORTC QLQ-C30 and FACT -G characteristics: mean scores, standard deviation, skweness and kurtosis
measurements and Cronbach’s Alpha
Instrument Scale Mean (SD) Skewness Kurtosis Cronbach’s Alpha
EORTC QLQ-C30 Physical functioning 0.69 0.27 -0.78 -0.27 0.87
Emotional functioning 0.63 0.24 0.14 0.39 0.46
Social functioning 0.68 0.25 -0.26 -0.84 0.89
Role functioning 0,55 0.33 -0.48 -0.85 0.96
Cognitive functioning 0.80 0.20 -1.78 1.13 0.27
Global Health Status 0.61 0.23 -0.36 -0.38 0.92
Fatigue 0.36 0.29 0.70 -0.43 0.85
Nausea/vomiting 0.10 0.21 2.50 5.90 0.79
Pain 0.33 0.28 0.68 -0.09 0.85
Dyspnoea 0.19 0.28 1.34 0.85 -
Insomnia 0.36 0.33 0.52 -0.79 -
Appetite loss 0.22 0.33 1.20 0.25 -
Constipation 0.15 0.26 1.73 2.37 -
Diarrhea 0.03 0.10 2.15 7.73 -
Financial difficulties 0.31 0.28 0.47 -0.70 -
FACT-G Physical well-being 0.71 0.22 -0.77 -0.22 0.89
Social/family well-being 0.66 0.17 -0.67 -1.23 0.71
Emotional well-being 0.62 0.17 0.09 -0.57 0.69
Functional well-being 0.51 0.19 0.18 0.73 0.84
Total 0.63 0.15 -0.24 -0.50 0.76
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pared in EORTC QLQ- H&N35. FACT - (H&N-G) was
found to sensitive when total score was considered and
identified the pharynx neoformation location by the low
scores found in the single items 1, 2, 5, 6 and 11. (Table 6)
Tumour size sensitivity
Patients with different tumour size are not depicted by
the FACT-G assessment and EORTC QLC-C30 is only
able to discriminate T3 and T4 when SF or the 2 simple
items Diarrhea and Financial difficulties are considered.
The EORTC QLQ- H&N35 scales Swallowing and
Trouble with social contact were found to be sensitive
for T3 and T4, the same tumour size identified by
FACT - (H&N-G) when total score and the single item
questions 5 and 11 are addressed. Patients with T3 and
T4 always presented the lowest scores. (Table 7)
Construct Validity
Internal convergent validity
The EORTC QLQ C-30’s revealed two correlations,
between scales PF - RF (0.79) and RF - SF (0.72),
whereas only one was found in FACT-G - between Fwb
and Pwb scales (0.70).
External convergent validity
The four domains covered by both HRQoL instruments
are illustrated in the MTMM correlation matrix shown
in Table 8.
A convergence between instruments was found for PF
and Pwb scales (0.80), PF and Fwb scales (0.71), SF and
Pwb scales (0.70), PF and Fwb scales (0.71).
Both Physical and Role functions depicted in EORTC
assessment revealed to correlate with either FACT-G
Physical and Functional well-being (0.80 for Pwb, 0.71
for Fwb and 0.75 for Pwb, 0.70 for Fwb, respectively).
Thus, for these two functional dimensions the two ques-
tionnaires seem to assess in a similar way. In opposition
the Social and Emotional scales were found to evaluate
the same issues but in a different way - Social function
revealed a correlation with the Physical well-being (0.70)
and no correlation were found for the Emotion function.
Discussion
Head and neck cancer affects mainly men (ratio male :
female ranges between 2 - 5:1, depending on tumour
location), contributing to 4% of deaths among males in
Portugal and represents the fifth cause of death with
cancer in men [31,32]. In the present study it was found
Table 5 Scores of the four corresponding HRQoL scales of EORTC QLQ-C30 and FACT-G for the two group of patients:
symptomatic and asymptomatic
EORTC and FACTG scores Symptomatic Asymptomatic Mann Whithney
(p value)
Mean (SD) 62% (n = 53) 38% (n = 32)
EORTC PF 35.64 55.19 0.000
FACT-G Pwb 33.77 58.28 0.000
EORTC SF 36.32 53.56 0.001
FACT-G Swb 40.50 47.14 0.225
EORTC EF 39.75 48.39 0.115
FACT-G Ewb 58.33 33.75 0.000
EORTC RF 51.78 37.70 0.008
FACT-G Fwb 57.44 34.28 0.000
PF = Physical function, SF = Social function, EF = Emotional function, R = Role function.
Pwb = Physical well-being, Swb = Social well-being, Ewb = Emotional well-being, Fwb = Functional well-being.
Table 4 EORTC H&N35 and FACT - (H&N-G) characteristics: mean scores, standard deviation, skweness and kurtosis
measurement, and Cronbach’s Alpha
Instrument Scale Mean (SD) Skewness Kurtosis Cronbach’s Alpha
EORTC H&N35 Pain 0.25 0.22 0.92 0.32 0.72
Swallowing 0.28 0.29 0.83 -0.34 0.90
Senses problems 0.20 0.30 1.42 0.85 0.70
Speech problems 0.35 0.34 0.79 -0.20 0.46
Trouble with social eating 0.24 0.29 1.14 0.25 0.92
Trouble with social contact 0.20 0.22 1.31 1.17 0.86
Less Sexuality 0.16 0.26 1.60 1.73 0.99
Total - - - - 0.90
FACT (H&N-G) Total - - - - 0.57
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kers with low literacy. The most frequent tumour loca-
tions identified is in agreement with literature
identifying the larynx as the most common site for head
and neck cancer, being squamous cell carcinoma the
preferential histopathology diagnostic[33-35].
Most cancer patients (54%) were in a symptomatic
phase although a high Karnofsky Index (90-100%) was
reported. These data emphases that the viewer’s percep-
tion is different from the patient self-perception
obtained by HRQoL assessment [36,37].
The instrument’s characteristics analysis revealed that
syntax is different between questionnaires: EORTC pro-
poses a mixed order of questions and FACT-G chooses
preferably statements organized into modules. The con-
tent of the EORTC questionnaires focuses on the every-
day situations observing mainly physical and symptoms,
and the FACT-G explores the existential problems and
personal satisfaction. The EORTC version used head not
a total score as FACT-G but presented a richer specific
questionnaire for head and neck cancer patients.
Although the EORTC questionnaires- QLQ C30 and
H&N 35- were administered separately and FACT H&N
just once (it includes the core questionnaire plus the
H&N specific module), more unanswered items (missing
data) were obtained with FACT-H&N being the sexual-
ity items the lesser answered. The fact that FACT-H&N
considers these items answer optional, may encourage
patients to not answer such questions and justify these
results, which are consistent with other studies reporting
a large proportion of missing data when considering the
Sexuality item [38,39]. Asymmetry and flatness measures
do not differentiate the questionnaires although EORTC
QLQ-C30 flattening measure revealed to be closer to a
normal distribution.
The higher variability found in EORTC QLQ- C30
functional scales and the leptokurtic distribution of Swb
d i m e n s i o ni nF A C T - Gs u g g e s tt h a tw h e na n s w e r i n g
FACT-G questionnaire, patients tend to respond in the
core values, reducing thus the effect of the measure.
Although both instruments showed good internal con-
sistency it was found to be higher in the EORTC
Table 6 Scores of the corresponding HRQoL scales of EORTC QLQ-C30 and FACT-G for the five group of patients
according to their tumour location
EORTC and FACTG scores Vocal cord Laryng Pharynx Pharynx laryngeal Tongue Kruskal-Wallis (p value)
Mean (SD) 18.8%
(n = 18)
17,7%
(n = 17)
13.5%
(n = 13)
6,3%
(n = 6)
5.2%
(n = 5)
EORTC PF 35.72 26.24 26.38 29.92 31.70 0.481
FACT-G Pwb 40.44 29.62 17.65 30.08 25.7 0.008
EORTC SF 34.28 27.91 24.23 30.50 36.10 0.438
FACT-G Swb 27.81 34.03 34.62 27.92 14.70 0.172
EORTC EF 31.14 29.50 28.27 31.42 30.40 0.992
FACT-G Ewb 34.11 34.09 23.25 24.17 25.60 0.286
EORTC RF 35.11 28.26 25.96 28.00 30.40 0.601
FACTG Fwb 34.36 33.44 22.08 21.17 33.80 0.166
PF = Physical function, SF = Social function, EF = Emotional function, R = Role function.
Pwb = Physical well-being, Swb = Social well-being, Ewb = Emotional well-being, Fwb = Functional well-being.
Table 7 Scores of the corresponding HRQoL scales of EORTC QLQ-C30 and FACT-G for the four group of patients
according to their tumour size
EORTC and FACTG scores T1 T2 T3 T4 Kruskal-Wallis
(p value)
Mean (SD) 10,8 %
(n = 11)
12,7 %
(n = 13)
17,6 %
(n = 18)
31,4 %
(n = 32)
EORTC PF 39.55 35.12 43.19 34.56 0.544
FACT-G Pwb 45.95 36.19 38.53 34.55 0.493
EORTC SF 47.27 47.15 29.92 34.48 0.037
FACT-G Swb 42.18 30.23 36.75 39.27 0.515
EORTC EF 42.55 42.08 37.75 33.77 0.533
FACT-G Ewb 41.82 38.15 38.08 35.42 0.855
EORTC RF 38.00 40.96 39.81 34.63 0.753
FACTG Fwb 50.55 41.27 37.64 31.41 0.070
PF = Physical function, SF = Social function, EF = Emotional function, R = Role function.
Pwb = Physical well-being, Swb = Social well-being, Ewb = Emotional well-being, Fwb = Functional well-being.
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Page 7 of 9questionnaires. Low reliability in Cognitive Function
scale from EORTC QLQ- C30 and FACT-(H&N-G)
may be explained by the conceptual characteristics of
these instruments. Both are good tools to distinguish
symptomatic patients, however, both questionnaires
show similar inefficiency differentiates tumour location.
The EORTC questionnaires also revealed sensitivity to
distinguish the two staging T3 and T4.
Just like other authors, it was found that administra-
tion of both questionnaires proved to be feasible, with
acceptable response times. The easy, acceptable and
understandable questionnaires format may facilitate its
potential inclusion in routine clinical protocols [38-40].
Conclusions
The data demonstrate that the EORTC QLQ-C30 (ver-
sion 3) and EORTC QLQ-H& N35 and FACT H&N
(Version 4) are good tools for HRQoL assessment in
head and neck cancer patients, although the psycho-
metric characteristics - fidelity, validity and sensitivity -
are different.
Thus, our results suggest that these two instruments
assess different aspects of QoL. The EORTC QLQ-C30
questionnaire provides a vision focused on physical and
symptoms aspects, while the FACT H&N gives a multi-
dimensional view of the concept, a broader perspective
and comprehensive description of different areas. These
results agree in general with other HRQoL instruments
comparative studies and demonstrate that a tool does
not replace the other and direct result comparison was
not possible. The questionnaires should be used sepa-
rately and chosen according to the study objectives and
methodology.
This study emphases the importance in selecting the
appropriate tool as a critical success factor in imple-
menting routine Health Related Quality of Life assess-
ment in clinical practice. This decision assumes
particularly importance when utilization of results in
real time and integration into clinical protocols is
considered.
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